Application No.: 10/597,938 PATENT Group Art Unit: 1615 1953233-00021

Response to Ex Parte Quayle Action of 12/23/10

**Amendments to the Claims**:

This listing of claims will replace all prior versions, and listings, of claims in the

application:

**Listing of Claims:** 

1. Cancelled

2. (Previously Presented) A sustained-release drug delivery device comprising a

structural element and a drug reservoir, wherein the drug reservoir comprises a coating

applied to the surface of the structural element and wherein the coating comprises an

inorganic mesoporous oxide with substantially continuously interconnected channels.

3. (Original) The sustained-release drug delivery device of claim 2 wherein the

majority of the interconnected channels have a diameter of between 1-100 nm.

4. (Original) The sustained-release drug delivery device of claim 3 wherein the

majority of the interconnected channels have a diameter of between 2 nm and 30 nm.

5. (Original) The sustained-release drug delivery device of claim 2 wherein the

mesoporous oxide is a triblock copolymer-template-based mesoporous oxide.

6. (Original) The sustained-release drug delivery device of claim 5 wherein the

mesoporous oxide is selected from the group consisting of: an oxide of silicon and an

oxide of titanium.

7. (Original) The sustained-release drug delivery device of claim 2 wherein the

interior surfaces of the interconnected channels are coated with an agent that modifies

hydrophobicity or charge.

8. (Original) The sustained-release drug delivery device of claim 7 wherein agent

that modifies hydrophobicity or charge comprises a silane coupling agent.

9. (Original) The sustained-release drug delivery device of claim 2 wherein the

drug reservoir coating is applied to the surface of the structural element by a method

- 4 -

Application No.: 10/597,938 PATENT Group Art Unit: 1615 1953233-00021

Response to Ex Parte Quayle Action of 12/23/10

selected from the group consisting of: dip-coating, spray coating, spin-coating and painting.

10. (Original) The sustained-release drug delivery device of claim 2 further comprising a drug loaded within the drug reservoir.

11. (Original) The sustained-release drug delivery device of claim 10 adapted for delivery of the drug for a period of at least 3 days.

12. (Original) The sustained-release drug delivery device of claim 11 adapted for delivery of the drug for a period of at least 7 days.

13. (Original) The sustained-release drug delivery device of claim 12 adapted for delivery of the drug for a period of at least 30 days.

14. (Cancelled)

15. (Original) The sustained-release drug delivery device of claim 10 wherein the drug is an anti-restenotic drug.

16. (Original) The sustained-release drug delivery device of claim 15 wherein the drug is a taxol-derived drug.

17. (Original) The sustained-release drug delivery device of claim 16 wherein the drug is selected from the group consisting of PACLITAXEL, SIROLIMUS, and TACROLIMUS.

- 18. (Original) The sustained-release drug delivery device of claim 15 wherein the drug delivery device is adapted for implantation into the vascular system of a subject.
- 19. (Original) The sustained-release drug delivery device of claim 18 wherein the drug delivery device comprises a stent.
- 20. (Previously Presented) The sustained-release drug delivery device of claim 19 wherein the total amount of drug loaded within the drug reservoir is between 1 and 1,000 micrograms per stent.

Application No.: 10/597,938 PATENT Group Art Unit: 1615 1953233-00021

Response to Ex Parte Quayle Action of 12/23/10

21. (Original) The sustained-release drug delivery device of claim 2 wherein the drug is selected from the group consisting of: an anti-inflammatory agent, an antimicrobial agent, and antineoplastic agent, and angiogenic agent, an anti-angiogenic agent, a thrombolytic agent, an antihypertensive agent, an anti-arrhythmic agent, a calcium channel blocker, a cholesterol-lowering agent, a psychoactive agent, an anti-depressive agent, an anti-seizure agent, a contraceptives, an analgesics, a bone growth factor, a bone remodeling factor, a neurotransmitter, and an opiate antagonist.

22. - 34. (Cancelled)